Goodwin

Elizabeth Mulkey

Deals
5
Latest
Jun 2026
Most deals in
Biotech

Firm

  • Goodwin Law firm · 2026 · 5 deals
Deals by year
Elizabeth Mulkey: deals by year0520252026 YTD: 4 M&A2026 YTD: 1 Equity raisings52026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Elizabeth Mulkey was named on, most recent first
Jun 2026 Parabilis Medicines ––PlacementLegal adviser to the issuerCompleted75.0Biotech+1Parabilis Medicines placement
May 2026 Perfuse Therapeutics –BayerAcquisitionLegal adviser to Perfuse Therapeutics (target)Announced300.0Biotech+2Bayer acquisition of Perfuse Therapeutics
May 2026 LimmaTech Biologics AG –Eli Lilly and CompanyAcquisitionLegal adviser to LimmaTech Biologics AG (target)Pending780.0BiotechEli Lilly and Company acquisition of LimmaTech Biologics AG
Apr 2026 Worldwide rights to Kenalog Bristol-Myers SquibbSubsidiary of Piramal PharmaAsset saleLegal adviser to subsidiary of Piramal Pharma (acquirer)Announced35.0PharmaSubsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog
Apr 2026 Tubulis EQT Life Sciences (LSP 7 fund)Gilead SciencesAcquisitionLegal adviser to Tubulis (target)Announced3,150.0Biotech+2Gilead Sciences acquisition of Tubulis

Deals where Elizabeth Mulkey is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.